Cancer Therapeutics Market to Reach US$491.60 Billion by 2032 as Precision Oncology, Immunotherapy and Targeted Therapy Reshape Global Treatment Strategies

NEW YORK, May 24, 2026 - According to DataM Intelligence, the global Cancer Therapeutics Market reached US$168.15 billion in 2024 and is expected to reach US$491.60 billion by 2032, growing at a CAGR of 12.6% during 2025 to 2032. The market is segmented by therapy into hormonal therapy, targeted therapy, chemotherapy, radiotherapy, immunotherapy and other therapies, and by cancer type into breast cancer, lung cancer, prostate cancer, blood cancer, cervical cancer, malignant meningioma, head and neck cancer and others.

The global cancer therapeutics market is entering a high-value expansion cycle as oncology care shifts from broad cytotoxic treatment toward precision medicine, immunotherapy, targeted therapy and biomarker-led drug development.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/cancer-therapeutics-market?kailas

Oncology Remains a Highly Sellable Market Because Demand Is Broad, Urgent and Recurring

Cancer therapeutics is commercially attractive because it is not dependent on a single disease type, a single treatment class or a single patient segment. The market covers high-burden cancer categories including breast cancer, lung cancer, prostate cancer, blood cancer, cervical cancer, head and neck cancer and other tumor types, giving the sector a diversified demand base across hospitals, cancer centers, research institutes, hospital pharmacies, retail pharmacies and online pharmacies.

The sellability of this market is strengthened by three factors: a large global patient population, continuous innovation across drug classes and sustained spending on cancer medicines. The World Health Organization reported an estimated 20 million new cancer cases and 9.7 million cancer deaths in 2022, while more than 35 million new cancer cases are projected by 2050, representing a 77% increase from 2022 levels. This rising disease burden gives oncology therapeutics a durable demand foundation across developed and emerging healthcare systems.

Treatment Spending Confirms Oncology's High-Value Commercial Profile

Cancer therapeutics continues to command strong healthcare spending because many therapies are used in serious, chronic, relapsed or advanced disease settings where clinical urgency is high. IQVIA reported that global cancer medicine spending at list prices reached US$252 billion in 2024 and is expected to reach US$441 billion by 2029, reflecting the continued expansion of branded oncology medicines, novel modalities and treatment duration.

This spending profile is one of the strongest reasons the category is sellable. Oncology is a treatment area where innovation can rapidly translate into premium pricing, payer negotiations, hospital adoption, specialist prescribing and pipeline-driven market expansion. As new therapies move into earlier lines of treatment and biomarker-defined patient populations expand, market value is expected to deepen across both solid tumors and hematologic malignancies.

Precision Oncology Is Redefining the Treatment Landscape

The most important shift in the cancer therapeutics market is the growing dominance of targeted therapy. DataM Intelligence identifies targeted therapy as the segment expected to dominate the global cancer therapeutics market because of its ability to attack cancer cells more precisely while reducing damage to healthy cells. This precision-oriented approach has changed oncology treatment strategy by linking drug selection to molecular targets, genetic alterations and tumor-specific pathways.

Targeted therapy's growth is being reinforced by a stronger understanding of cancer biology and the identification of new molecular targets across different cancer types. DataM Intelligence cites FDA approvals such as Eli Lilly's selpercatinib for RET fusion-positive solid tumors and Bristol Myers Squibb's Augtyro for NTRK gene fusion-positive solid tumors as examples of precision oncology expanding across biomarker-selected populations.

Pipeline Activity Keeps Oncology Commercially Active Year After Year

Cancer therapeutics remains highly sellable because the innovation cycle does not pause. IQVIA reported 2,162 oncology trial starts in 2024, up 12% from 2019, with novel oncology modalities such as cell and gene therapies, antibody-drug conjugates and multispecific antibodies accounting for 35% of oncology trials. The same report noted that 25 oncology novel active substances were launched globally in 2024, while 132 oncology novel active substances launched globally over the past five years.

This level of pipeline activity creates a constant need for market intelligence, competitive tracking, pricing analysis, clinical development monitoring and regional opportunity assessment. The oncology market evolves through new approvals, label expansions, combination regimens, biomarker testing, line-of-therapy movement and competitive displacement. That makes the category commercially dynamic and information-intensive.

Recent FDA Activity Reinforces the Pace of Innovation

The oncology approval environment continues to support market growth. The U.S. Food and Drug Administration's oncology and hematologic malignancies approval notifications list recent approvals across breast cancer, bladder cancer, acute myeloid leukemia, mantle cell lymphoma, cholangiocarcinoma and ovarian cancer, showing the breadth of active regulatory movement in 2026 alone.

This approval momentum matters because each new oncology approval can reshape treatment pathways, influence clinical guidelines, expand drug access and create new competitive benchmarks. DataM Intelligence also highlights recent key developments, including Loxo@Lilly's FDA approval of Jaypirca for relapsed or refractory mantle cell lymphoma in 2023 and Amgen's accelerated FDA approval for tarlatamab-dlle for extensive-stage small cell lung cancer in 2024.

Immunotherapy and Targeted Therapy Create a Premium Growth Engine

The market's growth is being driven by the evolution of immunotherapy, targeted therapy and combination treatment approaches. Immunotherapy uses the body's immune system to recognize and attack cancer cells, while targeted therapy focuses on specific molecular drivers associated with tumor growth. DataM Intelligence notes that immunotherapy has shown promise in cancers such as melanoma and lung cancer, while targeted therapy has advanced treatment in cancers such as breast and colorectal cancer.

IQVIA further notes that use of PD-1 and PD-L1 inhibitors has expanded in many high-income countries as these drugs move into pre-metastatic cancers, earlier therapy lines and tumor types supported by biomarker testing. Antibody-drug conjugates are also gaining adoption through new launches and broader eligible patient populations.

North America Holds the Dominant Market Position

North America is expected to dominate the global cancer therapeutics market, supported by strong research and development activity, frequent FDA approvals, major biopharmaceutical presence and increasing awareness of early diagnosis and treatment. DataM Intelligence identifies the region's advanced oncology ecosystem as a key reason for its leadership, with major companies introducing innovative drugs and expanding applications for targeted treatments and immunotherapies.

The region's dominance is also supported by strategic collaborations. DataM Intelligence cites AbbVie and EvolveImmune Therapeutics' October 2024 collaboration and option-to-license agreement to develop multispecific biologics for oncology targets, including therapies for solid and hematologic malignancies. These partnerships show how companies are using external innovation, platform technologies and licensing structures to strengthen oncology portfolios.

Asia Pacific Becomes the Fastest-Growing Opportunity Zone

Asia Pacific is growing at the fastest pace in the cancer therapeutics market due to rising cancer prevalence, increasing investment in research and development, and expanding adoption of targeted therapies and immunotherapies. DataM Intelligence notes that portfolio expansion by companies in the region is expected to increase Asia Pacific's share of cancer therapeutics market growth.

The region's growth potential is reinforced by improving healthcare infrastructure, expanding specialty care access, rising cancer awareness and increasing demand for innovative therapies. As diagnosis rates improve and cancer treatment capacity expands, Asia Pacific is expected to become a major growth engine for oncology therapeutics, particularly in high-incidence cancers and biomarker-led treatment segments.

Competitive Landscape: Global Oncology Leaders Compete Across Precision, Scale and Portfolio Depth

The global cancer therapeutics market includes major players such as F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie Inc., Astellas Pharma Inc., Pfizer Inc., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Amgen Inc. and AstraZeneca. These companies compete across targeted therapy, immunotherapy, chemotherapy, hormonal therapy, radiotherapy-linked treatment pathways and novel oncology modalities.

Competition is expected to intensify around biomarker-specific drugs, antibody-drug conjugates, bispecific antibodies, CAR-T therapies, checkpoint inhibitors, radiopharmaceuticals and combination regimens. IQVIA reports that novel modalities will contribute significantly to oncology spending growth through 2029, with antibody-drug conjugates and bispecific antibodies expected to grow meaningfully over the period.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-therapeutics-market?kailas

Strategic Outlook: Cancer Therapeutics Remains One of the Most Durable Pharmaceutical Growth Markets

The cancer therapeutics market is positioned for sustained expansion because it combines high unmet medical need, continuous pipeline movement, strong medicine spending and broad clinical applicability across multiple tumor types. The projected rise from US$168.15 billion in 2024 to US$491.60 billion by 2032 signals that oncology will remain one of the most commercially important areas of global healthcare.

The next phase of growth will be shaped by targeted therapy adoption, immunotherapy expansion, precision medicine, biomarker testing, earlier treatment-line movement, combination regimens, regional access improvement and continuous regulatory approvals. With cancer incidence rising globally and oncology R&D remaining highly active, cancer therapeutics stands out as a high-value, innovation-led and commercially resilient market category.

About the Report

The Cancer Therapeutics Market report by DataM Intelligence analyzes the market by therapy, cancer type, distribution channel, end-user and region. Therapy coverage includes hormonal therapy, targeted therapy, chemotherapy, radiotherapy, immunotherapy and other therapies. Cancer type coverage includes breast cancer, lung cancer, prostate cancer, blood cancer, cervical cancer, malignant meningioma, head and neck cancer and others. The report covers North America, Europe, Asia Pacific, South America, and the Middle East and Africa, along with competitive analysis, pipeline insights, unmet needs, regulatory compliance, opportunity analysis and strategic market intelligence.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.